Related Articles

News
STAT+: Up and down the ladder: The latest comings and goings
January 6, 2023
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. […]

News
STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs
May 26, 2023
San Francisco Biotechnology Network News
News, Syndication
Comments Off on STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs
The European Medicines Agency recommended revoking marketing authorization for a Novartis sickle cell disease drug called Adakveo. […]

News
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
September 7, 2022
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30%. […]